Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.52 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.44 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.44 |
| ▸ | HTR2B known ✓ | P41595 | 3/20 | 0.44 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL3218662 | 1.00 | SIGMAR1 (0.53) | SIGMAR1MEN1POLBKMT2ACYP3A4 | |
| SCHEMBL4718142 | 0.93 | MEN1 (0.59) | SIGMAR1MEN1POLBKMT2ABCHE | |
| Fumaric Acid SCHEMBL3221298 | 0.82 | KDM4E (0.48) | SIGMAR1MEN1POLBKMT2AKDM4E | |
| Fumaric Acid SCHEMBL3221286 | 0.82 | KDM4E (0.48) | SIGMAR1MEN1POLBKMT2AKDM4E | |
| Acetic Acid SCHEMBL3221646 | 0.81 | ALDH1A1 (0.42) | SIGMAR1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4761749 | 0.78 | ALDH1A1 (0.40) | MEN1POLBKMT2AKDM4EALDH1A1 | |
| Fumaric Acid SCHEMBL3220918 | 0.75 | HTR1A (0.42) | MEN1KMT2AKDM4EALDH1A1ALOX15 | |
| Fumaric Acid SCHEMBL3220938 | 0.75 | HTR1A (0.42) | MEN1KMT2AKDM4EALDH1A1ALOX15 | |
| SCHEMBL3214830 | 0.74 | GRIN2B (0.40) | MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4714296 | 0.74 | KDM4E (0.47) | SIGMAR1MEN1POLBKMT2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-08-07 | — | — | US | disclosed |
| US-20100041698-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, HTR1A, HTR2C | MEN1 2777/4885KMT2A 3808/4885HTR2A 5/4885 |
| US-20100041698-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, HTR1A, HTR2C | MEN1 2777/4885KMT2A 3808/4885HTR2A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.